Changyao Group(300391)
Search documents
8家上市公司被立案或处罚
第一财经· 2025-11-09 12:15
Core Viewpoint - The article highlights the ongoing strict regulatory environment in the A-share market, with multiple companies facing investigations and penalties for violations related to information disclosure and financial misconduct [3][11]. Group 1: Regulatory Actions - Eight listed companies disclosed investigations or penalties from the China Securities Regulatory Commission (CSRC) for violations such as information disclosure and insider trading [3][5]. - Companies involved include Bayi Steel, Delisted Haiyue, and ST Changyao, with specific allegations ranging from financial data falsification to insider trading [5][6]. - The regulatory stance emphasizes that delisting does not exempt companies from accountability, marking a shift in enforcement where violations will be pursued relentlessly [3][11]. Group 2: Specific Cases of Investigation - Bayi Steel and ST Changyao are under investigation for information disclosure violations and false financial reporting, respectively [5][6]. - Delisted Haiyue's controlling shareholder is being investigated for information disclosure violations, while Intercontinental Oil and Shanghai Xiba are facing scrutiny for short-term trading and shareholder trading violations [5][6]. - Companies like Intercontinental Oil claim that the investigations do not impact their operations, asserting normal business continuity [6]. Group 3: Administrative Penalties - Three companies, including Delisted Longyu, ST Tian Sheng, and ST Jintai, received administrative penalties, with Delisted Longyu facing significant fines for years of financial fraud [7][8]. - Delisted Longyu was found to have inflated revenue by approximately 14.54 billion yuan and profits by 37.32 million yuan through fictitious trading activities from 2019 to 2022 [9]. - ST Jintai and ST Tian Sheng also faced penalties for failing to disclose annual reports on time and for profit inflation in previous financial statements [10][12]. Group 4: Broader Implications - The article notes that even companies that have been delisted are not escaping penalties, with several facing investigations for past violations [11][12]. - Recent statistics indicate that multiple companies have been penalized for failing to disclose annual reports or for falsifying financial data, reflecting a broader trend of increased regulatory scrutiny in the market [14][15].
股价迎考!*ST长药涉嫌财务造假遭立案,存强制退市风险
Bei Jing Shang Bao· 2025-11-09 11:16
Core Viewpoint - *ST Changyao has been placed under delisting risk warning due to operational pressures and has now received further negative news regarding a formal investigation by the China Securities Regulatory Commission (CSRC) for suspected false financial reporting [1][3]. Financial Performance - For the years 2022 to 2024, *ST Changyao reported revenues of approximately 1.615 billion, 1.198 billion, and 112 million respectively, with net profits of -23 million, -606 million, and -628 million [3]. - In the first three quarters of this year, the company achieved a revenue of 105 million, a year-on-year increase of 4.4%, while the net profit was -210 million, a year-on-year decrease of 15.89% [4]. Regulatory and Legal Issues - The CSRC has issued a notice of investigation due to suspected false recording of financial data, which could lead to significant legal repercussions for the company [1][3]. - If the CSRC confirms violations that meet the criteria for mandatory delisting under the Shenzhen Stock Exchange rules, the company's stock may face forced delisting [3]. Asset and Debt Situation - As of the end of the third quarter, *ST Changyao's net assets were reported at -643 million, worsening from -433 million at the end of 2024 [3]. - The company is currently undergoing a pre-restructuring phase, with a court decision extending this period until January 20, 2026 [4]. Bankruptcy and Restructuring Risks - The company faces significant risks related to its restructuring process, including the possibility of failure to pass restructuring plans or court approval, which could lead to bankruptcy [5]. - There are currently 140 ongoing lawsuits and arbitration cases involving the company, with a total amount in dispute of 1.878 billion, representing 434% of the company's latest audited net assets [5].
*ST长药(300391)被证监会立案!或强制退市
Zheng Quan Shi Bao· 2025-11-08 00:24
Core Viewpoint - *ST Changyao has been under investigation by the China Securities Regulatory Commission (CSRC) for suspected false reporting of financial data, which could lead to a forced delisting if major violations are confirmed [2]. Financial Performance - As of December 31, 2024, *ST Changyao reported a negative net asset of 433 million yuan and an accumulated loss of 1.59 billion yuan [2]. - In the first three quarters of 2025, the company's revenue increased by 4.40% year-on-year to 105 million yuan, while the net profit attributable to shareholders decreased by 15.89% to -210 million yuan [2]. - The net profit excluding non-recurring items fell by 16.99% to -209 million yuan, with net assets further declining to -643 million yuan [2]. Stock Performance - As of November 7, *ST Changyao's stock price was 3.45 yuan per share, down 0.58%, with a total market capitalization of 1.209 billion yuan [2][3]. - The stock has shown a trading volume of 75,300 shares, with a turnover rate of 2.15% [3].
300391,被证监会立案!或强制退市

Sou Hu Cai Jing· 2025-11-07 16:09
Core Viewpoint - *ST Changyao's financial performance remains weak, with negative net assets and declining profits despite a slight increase in revenue [1][2] Financial Performance - As of December 31, 2024, *ST Changyao's net assets attributable to shareholders were -433 million CNY, and retained earnings were -1.59 billion CNY [1] - In the first three quarters of 2025, the company reported a revenue increase of 4.40% year-on-year to 105 million CNY, but net profit attributable to shareholders decreased by 15.89% to -210 million CNY [1] - The company's net profit excluding non-recurring items fell by 16.99% year-on-year to -209 million CNY, with net assets attributable to shareholders at -643 million CNY [1] Stock Performance - As of November 7, *ST Changyao's stock price was 3.45 CNY per share, down 0.58%, with a total market capitalization of 1.209 billion CNY [1][2] - The stock has shown a trading volume of 75,300 shares and a turnover rate of 2.15% [2]
300391 被证监会立案!或强制退市

Zheng Quan Shi Bao· 2025-11-07 15:43
Core Viewpoint - *ST Changyao has been subjected to an investigation by the China Securities Regulatory Commission (CSRC) due to suspected false financial reporting, which could lead to a forced delisting if significant violations are confirmed [2]. Financial Performance - As of December 31, 2024, *ST Changyao reported a negative net asset of -433 million yuan and an undistributed profit of -1.59 billion yuan [2]. - For the first three quarters of 2025, the company's revenue increased by 4.40% year-on-year to 105 million yuan, while the net profit attributable to shareholders decreased by 15.89% to -210 million yuan [2]. - The net profit excluding non-recurring items fell by 16.99% year-on-year to -209 million yuan, with net assets dropping to -643 million yuan [2]. Stock Performance - As of November 7, *ST Changyao's stock price was 3.45 yuan per share, reflecting a decline of 0.58%, with a total market capitalization of 1.209 billion yuan [2][3].
300391,被证监会立案!或强制退市
证券时报· 2025-11-07 15:43
Core Viewpoint - *ST Changyao has been under investigation by the China Securities Regulatory Commission (CSRC) for suspected false reporting of financial data, which could lead to significant legal consequences and potential delisting if major violations are confirmed [1]. Financial Performance Summary - As of December 31, 2024, *ST Changyao reported a negative net asset of -433 million yuan and an undistributed profit of -1.59 billion yuan [1]. - For the first three quarters of 2025, the company experienced a revenue increase of 4.40% year-on-year, reaching 105 million yuan; however, the net profit attributable to shareholders decreased by 15.89% to -210 million yuan, and the non-recurring net profit fell by 16.99% to -209 million yuan [1]. - The net asset value as of the reporting period was -643 million yuan [1]. Stock Market Performance - As of November 7, *ST Changyao's stock price was 3.45 yuan per share, reflecting a decrease of 0.58%, with a total market capitalization of 1.209 billion yuan [2]. - The trading volume was 75,300 shares, with a turnover rate of 2.15% [2]. - The stock has a price-to-earnings (PE) ratio of -4.32 and a price-to-book (PB) ratio of -1.88 [2].
300391 被证监会立案!涉嫌财务造假 或强制退市
Zhong Guo Ji Jin Bao· 2025-11-07 15:01
Core Viewpoint - *ST Changyao is facing a critical survival challenge due to the China Securities Regulatory Commission's investigation, the looming risk of delisting, and difficulties in its pre-restructuring process [2][3][4] Financial Situation - As of December 31, 2024, *ST Changyao reported a negative net asset of -433 million yuan and an accumulated loss of -1.59 billion yuan, with a net profit of -628 million yuan for the year [4] - The company's revenue has drastically declined from 1.615 billion yuan in 2022 to 1.198 billion yuan in 2023, and further down to only 112 million yuan in 2024 [5] - For the first three quarters of 2025, *ST Changyao's revenue increased by 4.4% year-on-year to 105 million yuan, but the net profit decreased by 15.89% to -210 million yuan [5] Delisting Risk - The company is under significant threat of mandatory delisting due to its negative net asset situation and the potential for administrative penalties from the CSRC [2][3][6] - If *ST Changyao fails to improve its financial performance in Q4 2025, it will trigger the delisting clause related to negative net assets [6] Restructuring Challenges - Prior to the CSRC investigation, *ST Changyao was already struggling with debt, leading to the initiation of pre-restructuring by the Hubei Province Shiyan Intermediate People's Court on January 20, 2025 [7] - The court has extended the pre-restructuring period until January 20, 2026, indicating slow progress in the restructuring efforts [8] - The company has warned of the uncertainty surrounding its ability to enter formal restructuring and the risk of bankruptcy if restructuring fails [9] Legal and Financial Liabilities - Due to overdue debts, several creditors have initiated lawsuits against *ST Changyao, resulting in the freezing of numerous bank accounts and asset seizures [11] - As of October 20, 2025, the company had significant interest-bearing liabilities totaling 1.106 billion yuan, with 390 million yuan overdue [11] - The company is involved in 140 legal cases with a total amount in dispute of 1.878 billion yuan, which is 434% of its latest audited net assets [11] Market Performance - As of November 7, 2025, *ST Changyao's stock price was 3.45 yuan per share, with a total market capitalization of only 1.209 billion yuan [13]
300391,被证监会立案!涉嫌财务造假,或强制退市
中国基金报· 2025-11-07 14:54
Core Viewpoint - *ST Changyao is facing a critical situation due to a formal investigation by the China Securities Regulatory Commission (CSRC) for suspected financial data falsification, which may lead to mandatory delisting risks and ongoing pre-restructuring challenges [2][4]. Financial Risks - The company has been under the shadow of delisting due to severe financial issues, with a negative net asset value of -433 million yuan as of December 31, 2024, and an accumulated loss of -1.59 billion yuan [7]. - Revenue has drastically declined from 1.615 billion yuan in 2022 to 1.198 billion yuan in 2023, with projections of only 112 million yuan for 2024 [8]. - For the first three quarters of 2025, the company reported a 4.4% year-on-year revenue increase to 105 million yuan, but net profit decreased by 15.89% to -210 million yuan [8]. Delisting Risks - If *ST Changyao fails to improve its financial performance in Q4 2025, it will trigger the delisting clause due to negative audited net assets [9]. - The company has been under a delisting risk warning since April 22, 2025, following a negative net asset report for the 2024 fiscal year [6]. Pre-restructuring Challenges - Prior to the CSRC investigation, *ST Changyao was already struggling with debt, leading to a pre-restructuring process initiated by the Hubei Province Shiyan Intermediate People's Court on January 20, 2025 [11]. - The court has extended the pre-restructuring period until January 20, 2026, indicating difficulties in the restructuring process [11]. - The company has warned of the risk of bankruptcy if the restructuring fails, despite several subsidiaries already undergoing restructuring [13][14]. Legal and Financial Liabilities - The company faces significant legal challenges, with 140 lawsuits involving a total of 1.878 billion yuan, which is 434% of its latest audited net assets [15]. - As of October 20, 2025, *ST Changyao reported total interest-bearing liabilities of 1.106 billion yuan, with 390 million yuan overdue [15]. - A substantial number of bank accounts (67.7%) have been frozen due to overdue debts, severely impacting the company's financial operations [15][16]. Market Performance - As of November 7, 2025, *ST Changyao's stock price was 3.45 yuan per share, with a total market capitalization of 1.209 billion yuan [17].
300391,立案调查!或强制退市!
Shang Hai Zheng Quan Bao· 2025-11-07 13:46
Core Viewpoint - *ST Changyao has been under investigation by the China Securities Regulatory Commission (CSRC) for suspected false reporting of financial data, which could lead to significant legal consequences and potential delisting of its stock [2][5][9] Financial Performance - The company's financial performance has deteriorated significantly, with operating revenue dropping from 16.15 billion in 2022 to 1.12 billion in 2024, a decline of over 90% [5] - The net assets of *ST Changyao were reported at -4.33 billion at the end of 2024 and further declined to -6.43 billion by the end of Q3 2025, indicating an imminent risk of financial delisting [2][5] - The company has incurred substantial losses, with net profits excluding non-recurring items reported at -6.32 billion in 2023 and -5.69 billion in 2024 [5] Debt and Legal Issues - As of Q3 2025, *ST Changyao has significant overdue debts totaling 3.9 billion out of 11 billion in interest-bearing liabilities, with 140 ongoing lawsuits involving a total amount of 18.8 billion [5][7] - The company has had 67.7% of its bank accounts frozen, totaling 109 accounts, due to these legal and financial issues [5] Compliance and Governance - The company has a history of regulatory violations, including unauthorized financial assistance and guarantees, as well as failure to disclose significant lawsuits and overdue debts in a timely manner [7] - Specific violations include providing 1.8 billion in financial assistance to a related party, which constituted 92% of the latest audited net assets, and failing to disclose 25 lawsuits totaling 2.02 billion from May 2021 to May 2023 [7] Restructuring and Delisting Risks - The company is currently undergoing pre-restructuring proceedings initiated by the Shiyan Intermediate People's Court, but its potential for successful restructuring is uncertain due to the ongoing investigation and financial issues [9] - If the CSRC confirms the violations, *ST Changyao may face mandatory delisting under the Shenzhen Stock Exchange's rules for significant legal infractions [9]
*ST长药涉嫌财务造假被立案 多重危机下退市风险高企
Zheng Quan Ri Bao Wang· 2025-11-07 13:25
11月7日,长江医药控股股份有限公司(以下简称"*ST长药(300391)")公告称,公司收到中国证监会下 发的《立案告知书》,因公司涉嫌定期报告等财务数据虚假记载,根据《中华人民共和国证券法》《中 华人民共和国行政处罚法》等法律法规,中国证监会决定对公司立案。 公告显示,若后续经中国证监会行政处罚认定的事实,触及《深圳证券交易所创业板股票上市规则》规 定的重大违法强制退市情形,*ST长药股票将被实施重大违法强制退市。 而回溯公司过往公告,诸多风险隐患早已显现,叠加此次财务真实性相关的立案调查,*ST长药的经营 与资本层面均已陷入多重危机,广大投资者应充分评估相关风险。 在经营陷入困境的同时,*ST长药的内控漏洞也不断暴露,多次发生违规操作且未履行信息披露义务。 经营状况持续恶化 具体来看,在资金管理方面,截至2023年末,公司向时任董事、总经理罗明控制的企业累计违规提供财 务资助1.8亿元,该金额占公司最近一期经审计净资产的92%,尽管这笔资金在2024年通过关联方债权 债务转让等方式收回,但违规行为已严重违反规范运作要求。 此外,公司控股孙公司还曾未经审议便对外提供809.2万元的关联担保,占最近一期经审 ...